Cefalexin 250mg/5ml oral suspension sugar free

Country: United Kingdom

Language: English

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Active ingredient:

Cefalexin

Available from:

Milpharm Ltd

ATC code:

J01DB01

INN (International Name):

Cefalexin

Dosage:

50mg/1ml

Pharmaceutical form:

Oral suspension

Administration route:

Oral

Class:

No Controlled Drug Status

Prescription type:

Valid as a prescribable product

Product summary:

BNF: 05010201; GTIN: 5060035110766

Patient Information leaflet

PACKAGE LEAFLET: INFORMATION FOR THE USER
CEFALEXIN 125MG/5ML POWDER FOR ORAL SUSPENSION
CEFALEXIN 250MG/5ML POWDER FOR ORAL SUSPENSION
(cefalexin)
READ ALL OF THIS LEAET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT
CONTAINS IMPORTANT INFORMATION FOR YOU.
-
Keep this leaet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It
may harm them, even if their signs of illness are the same as yours
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any
possible side effects not listed in this leaet. See section 4.
WHAT IS IN THIS LEAET:
1.
What Cefalexin Oral Suspension is and what it is used for
2.
What you need to know before you take Cefalexin Oral Suspension
3.
How to take Cefalexin Oral Suspension
4.
Possible side effects
5.
How to store Cefalexin Oral Suspension
6.
Contents of the pack and other information 1. WAT CEFALEXIN ORAL SUSPENSION IS AND WHAT IT IS USED FOR
Cefalexin Oral Suspension contain cefalexin as the active ingredient,
which belongs to a class
of antibiotics called 'cephalosporins'.
Cefalexin Oral Suspension is used to treat following infections caused
by bacteria that can be
killed by cefalexin:
•
Respiratory tract (lung and airways) e.g. tonsillitis, pharyngitis and
bronchitis
•
Middle ear infections (otitis media)
•
Skin and soft tissue (e.g. muscle) infections
•
Bone and joint infections
•
Infections of the reproductive organs and urinary tract (e.g.
cystitis), including
acute inammation of the prostate gland (prostatitis)
•
Dental infections. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE CEFALEXIN ORAL SUSPENSION
DO NOT TAKE CEFALEXIN ORAL SUSPENSION IF YOU:
•
Are allergic (hypersensitive) to cefalexin, other cephalosporins
(similar antibiotics) or
penicillin group of antibiotics, or to any of the ingredients in the
product (see Section
6 and end of Section 2). An allergic reaction may include rash,
i

Summary of Product characteristics

OBJECT 1
CEFALEXIN 250MG/5ML ORAL SUSPENSION
Summary of Product Characteristics Updated 13-Jun-2018 | Aurobindo
Pharma - Milpharm Ltd.
1. Name of the medicinal product
Cefalexin 250mg/5ml Powder for Oral Suspension
2. Qualitative and quantitative composition
Each 5ml contains Cefalexin 250mg (as Monohydrate) after
reconstitution.
For excipients, see 6.1.
3. Pharmaceutical form
Powder for Oral Suspension.
A pale yellow, free flowing granular powder, which readily disperses
in water to give a yellow
suspension with an odour of orange.
4. Clinical particulars
4.1 Therapeutic indications
Cefalexin is a semi synthetic cephalosporin antibiotic for oral
administration.
Cefalexin is indicated in the treatment of the following infections:
Respiratory tract infections; otitis
media; skin and soft tissue infections; bone and joint infections;
genito-urinary infections, including acute
prostatitis and dental infections.
Cefalexin is active against the following organisms in vitro:
β-haemolytic streptococci; staphylococci,
including coagulase-positive, coagulase-negative and
penicillinase-producing strains; Streptococcus
pneumoniae; Escherichia coli; Proteus mirabilis; Klebsiella species,
Haemophilus influenza; Branhamella
catarrhalis.
Most strains of enterococci (Streptococcus faecalis) and a few strains
of staphylococci are resistant to
cefalexin. Cefalexin is inactive against most strains of enterobacter,
morganella morganii, pr. Vulgaris,
colstridium difficule, and the following species: legionella,
campylobacter, pseudomonas or herellea
species. When tested by in vitro methods, staphylococci exhibit
cross-resistance between cefalexin and
methicillin-type antibiotics.
4.2 Posology and method of administration
Adults
1-4 g daily in divided doses; most infections will respond to a dosage
of 500 mg every 8 hours.
For skin and soft tissue infections, streptococcal pharyngitis and
mild, uncomplicated urinary tract
infections, the usual dosage is 250 mg every 6 hours, or 500 mg every
12 hours.
More severe infections, or those